Escin Suppresses Migration and Invasion Involving the Alteration of CXCL16/CXCR6 Axis in Human Gastric Adenocarcinoma AGS Cells

REFERENCES

• Parkin DM, Bray F, Ferlay J, and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55, 74–108, 2005.
   PubMed Web of Science ®Google Scholar
• Maruyama K, Gunven P, Okabayashi K, Sasako M, and Kinoshita T: Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg 210, 596–602, 1989.
   PubMed Web of Science ®Google Scholar
• Werner M, Becker KF, Keller G, and Hofler H: Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol 127, 207–216, 2001.
   PubMed Web of Science ®Google Scholar
• Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, et al.: Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 8, 86–94, 2005.
   PubMedGoogle Scholar
• Leber MF and Efferth T: Molecular principles of cancer invasion and metastasis (review). Int J Oncol 34, 881–895, 2009.
   PubMed Web of Science ®Google Scholar
• Fidler IJ: The organ microenvironment and cancer metastasis. Differentiation 70, 498–505, 2002.
   PubMed Web of Science ®Google Scholar
• Gomperts BN and Strieter RM: Chemokine-directed metastasis. Contrib Microbiol 13, 170–190, 2006.
   PubMedGoogle Scholar
• Deng L, Chen N, Li Y, Zheng H, and Lei Q: CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer. Biochim Biophys Acta 1806, 42–49, 2010.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wang J, Xu Y, Koch AE, Cai Z, et al.: CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res 6, 546–554, 2008.
   PubMed Web of Science ®Google Scholar
• Wang J, Lu Y, Koch AE, Zhang J, and Taichman RS: CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res 68, 10367–10376, 2008.
   PubMed Web of Science ®Google Scholar
• Xing YN, Xu XY, Nie XC, Yang X, Yu M, et al.: Role and clinicopathologic significance of CXC chemokine ligand 16 and chemokine (C-X-C motif) receptor 6 expression in gastric carcinomas. Hum Pathol 43, 2299–2307, 2012.
   PubMed Web of Science ®Google Scholar
• Matsuda H, Li Y, Murakami T, Ninomiya K, Yamahara J, et al.: Effects of escins Ia, Ib, IIa, and IIb from horse chestnut, the seeds of Aesculus hippocastanum L., on acute inflammation in animals. Biol Pharm Bull 20, 1092–1095, 1997.
   PubMed Web of Science ®Google Scholar
• Guillaume M and Padioleau F: Veinotonic effect, vascular protection, antiinflammatory and free radical scavenging properties of horse chestnut extract. Arzneimittel-Forschung 44, 25–35, 1994.
   PubMed Web of Science ®Google Scholar
• Ji DB, Xu B, Liu JT, Ran FX, and Cui JR: beta-Escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells. Mol Carcinog 50, 945–960, 2011.
   PubMed Web of Science ®Google Scholar
• Patlolla JM, Raju J, Swamy MV, and Rao CV: Beta-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21(waf1/cip1) in colon cancer cells. Mol Cancer Ther 5, 1459–1466, 2006.
   PubMed Web of Science ®Google Scholar
• Shen DY, Kang JH, Song W, Zhang WQ, Li WG, et al.: Apoptosis of human cholangiocarcinoma cell lines induced by beta-escin through mitochondrial caspase-dependent pathway. Phytother Res 25, 1519–1526, 2011.
   PubMed Web of Science ®Google Scholar
• Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, et al.: Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 334, 285–293, 2010.
   PubMed Web of Science ®Google Scholar
• Wang XH, Xu B, Liu JT, and Cui JR: Effect of beta-escin sodium on endothelial cells proliferation, migration and apoptosis. Vasc Pharmacol 49, 158–165, 2008.
   PubMed Web of Science ®Google Scholar
• Zhou XY, Fu FH, Li Z, Dong QJ, He J, et al.: Escin, a natural mixture of triterpene saponins, exhibits antitumor activity against hepatocellular carcinoma. Planta Med 75, 1580–1585, 2009.
   PubMed Web of Science ®Google Scholar
• Harper J and Moses MA: Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS 96, 223–268,sxst 2006.
   PubMedGoogle Scholar
• Kim EJ, Holthuizen PE, Park HS, Ha YL, Jung KC, et al.: Trans-10,cis-12-conjugated linoleic acid inhibits Caco-2 colon cancer cell growth. Am J Physiol Gastrointest Liver Physiol 283, G357–G367, 2002.
   PubMed Web of Science ®Google Scholar
• Kwon GT, Cho HJ, Chung WY, Park KK, Moon A, et al.: Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. J Nutr Biochem 20, 663–676, 2009.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim WK, Kim EJ, Jung KC, Park S, et al.: Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line. Am J Physiol Gastrointest Liver Physiol 284, G996–G1005, 2003.
   PubMed Web of Science ®Google Scholar
• Saklani A and Kutty SK: Plant-derived compounds in clinical trials. Drug Discov Today 13, 161–171, 2008.
   PubMed Web of Science ®Google Scholar
• Karikas GA: Anticancer and chemopreventing natural products: some biochemical and therapeutic aspects. J BUON 15, 627–638, 2010.
   PubMed Web of Science ®Google Scholar
• Ming ZJ, Hu Y, Qiu YH, Cao L, and Zhang XG: Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. Phytomedicine 17, 575–580, 2010.
   PubMed Web of Science ®Google Scholar
• Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S, et al.: Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol 77, 818–827, 2010.
   PubMed Web of Science ®Google Scholar
• Wang YW, Wang SJ, Zhou YN, Pan SH, and Sun B: Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol 138, 785–797, 2012.
   PubMed Web of Science ®Google Scholar
• Gutwein P, Schramme A, Sinke N, Abdel-Bakky MS, Voss B, et al.: Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer 45, 478–489, 2009.
   PubMed Web of Science ®Google Scholar
• Meijer J, Ogink J, Kreike B, Nuyten D, de Visser KE, et al.: The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. Cancer Res 68, 4701–4708, 2008.
   PubMed Web of Science ®Google Scholar
• Lin S, Sun L, Hu J, Wan S, Zhao R, et al.: Chemokine C-X-C motif receptor 6 contributes to cell migration during hypoxia. Cancer Lett 279, 108–117, 2009.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang J, Cui ZM, Zhao J, and Zheng Y: Expression of the CXCL12/CXCR4 and CXCL16/CXCR6 axes in cervical intraepithelial neoplasia and cervical cancer. Chinese J Cancer 32, 289–296, 2013.
   PubMedGoogle Scholar
• Wente MN, Gaida MM, Mayer C, Michalski CW, Haag N, et al.: Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol 33, 297–308, 2008.
   PubMed Web of Science ®Google Scholar
• Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, et al.: High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 67, 4725–4731, 2007.
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, et al.: Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280, 22473–22481, 2005.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun Y, Song W, Nor JE, Wang CY, et al.: Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal 17, 1578–1592, 2005.
   PubMed Web of Science ®Google Scholar
• Qin J, Tang J, Jiao L, Ji J, Chen WD, et al.: A diterpenoid compound, excisanin A, inhibits the invasive behavior of breast cancer cells by modulating the integrin beta1/FAK/PI3K/AKT/beta-catenin signaling. Life Sci 93, 655–663, 2013.
   PubMed Web of Science ®Google Scholar
• Keely PJ: Mechanisms by which the extracellular matrix and integrin signaling act to regulate the switch between tumor suppression and tumor promotion. J Mammary Gland Biol Neoplasia 16, 205–219, 2011.
   PubMed Web of Science ®Google Scholar
• Jung HJ, Jeon YH, Bokara KK, Koo BN, Lee WT, et al.: Agmatine promotes the migration of murine brain endothelial cells via multiple signaling pathways. Life Sci 92, 42–50, 2013.
   PubMed Web of Science ®Google Scholar
• Cobb MH: MAP kinase pathways. Prog Biophys Mol Biol 71, 479–500, 1999.
   PubMed Web of Science ®Google Scholar
• Cagnol S, Van Obberghen-Schilling E, and Chambard JC: Prolonged activation of ERK1,2 induces FADD-independent caspase 8 activation and cell death. Apoptosis 11, 337–346, 2006.
   PubMed Web of Science ®Google Scholar